Markets

Idexx Laboratories Sees Composite Rating Move Up To 96

Shutterstock photo

On Friday, Idexx Laboratories ( IDXX ) got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.

[ibd-display-video id=3105496 width=50 float=left autostart=true] The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.

Idexx Laboratories is trading about 5% above a 173.11 entry from a consolidation .

Looking For Winning Stocks? Try This Simple Routine

The stock has a 92 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth is outpacing 92% of all stocks.

Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.

In Q4, the company reported 21% earnings-per-share growth. Revenue growth increased 14%, up from 10% in the prior report. The company has now posted rising growth in each of the last two reports.

Idexx Laboratories holds the No. 4 rank among its peers in the Medical-Systems/Equipment industry group. Cantel Medical ( CMD ) is the No. 1-ranked stock within the group.

RELATED:

Which Companies Are Now Outperforming 95% Of All Stocks?

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CMD IDXX

Other Topics

Stocks

Latest Markets Videos